Who is sponsoring NCT04664582?

NCT04664582 is sponsored by Jewish General Hospital.

What drugs are being tested in NCT04664582?

Interventions in NCT04664582: Sentinel Lymph Node Biopsy.

What condition does NCT04664582 study?

NCT04664582 studies Cutaneous Squamous Cell Carcinoma, Sentinel Lymph Node.

Is NCT04664582 still recruiting?

NCT04664582 is currently status unknown. Last updated 5 April 2022.

Last reviewed 2022-04-05 · How we verify

NCT04664582

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Status unknown NA Last updated 5 April 2022

What this trial tests

NA trial testing Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma in 100 participants. Status unknown.

Timeline

26 November 2020

Primary endpoint
30 December 2022

30 December 2023

Quick facts

Lead sponsor	Jewish General Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	26 November 2020
Primary completion	30 December 2022
Estimated completion	30 December 2023
Sites	1 location across Canada

Drugs / interventions tested

Sentinel Lymph Node Biopsy

Conditions studied

Cutaneous Squamous Cell Carcinoma — all drugs for Cutaneous Squamous Cell Carcinoma →
Sentinel Lymph Node — all drugs for Sentinel Lymph Node →

Sponsor

Jewish General Hospital

Who can join

18 and older, any sex, with Cutaneous Squamous Cell Carcinoma or Sentinel Lymph Node. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Current guidelines in management of regional lymph node metastases for cSCC patients include surgical resection with or without adjuvant therapy as well as chemotherapy and interdisciplinary management; in advanced disease, supportive and palliative care is recommended. These guidelines also define the role of SLNB in management of high-risk cSCC as unclear and suggest further studies need to determine its utility and indications11. Currently, routine practice of performing SLNB in cSCC varies across Quebec and within Canada. At many institutions, SLNB is not routinely performed on patients with cSCC. The current standard of treatment is to observe closely when a patient is deemed to have a high-risk cancer, and if they have clinical or radiological findings of lymphadenopathy, a formal surgical neck dissection is performed. Given the comorbidities and risks involved in treatment of regional lymph nodes in cSCC, the role of SLNB in cSCC patients needs further clarification. This multicentre prospective study aims to better clarify this role and formulate suggested criteria for its indications.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Role of Sentinel Lymph Node Biopsy for Skin Cancer Based on Clinical Studies.
Ishizuki S, Nakamura Y. · · 2023 · cited 5× · PMID 37444401 · DOI 10.3390/cancers15133291

Verify or expand the search:

Other trials of Sentinel Lymph Node Biopsy

Trials testing the same drug.

NCT07121595 — Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cel · Phase 2 · recruiting
NCT05797415 — Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers · recruiting
NCT04959474 — Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer · NA · recruiting
NCT05004623 — Early Feasibility Study of the "Easy Light" Fluorecence Imaging System · NA · completed
NCT04333537 — Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cance · Phase 2, PHASE3 · recruiting

Other recruiting trials for Cutaneous Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
NCT07402616 — Ex Vivo Cutaneous SCC · NA · recruiting
NCT06875609 — ctDNA in Cutaneous Squamous Cell Carcinoma · recruiting
NCT06567314 — Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma · Phase 2 · recruiting
NCT06659146 — Thermotherapy in Addition to SOC Palliative Radiotherapy · NA · recruiting

Other Jewish General Hospital trials

Trials by the same sponsor.

NCT05188222 — Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery · Phase 4 · not yet recruiting
NCT06701929 — The Impact of Fasting Duration on Quality of Recovery After Cesarean Section · recruiting
NCT05719415 — Functional Pulmonary Capillary Surface Area in BPA for CTEPH · NA · recruiting
NCT04678986 — ER2 and Deep Learning for Prediction of Adverse Health Outcomes · withdrawn
NCT04893876 — The OPERa Study: Evaluating QoL After Rectal Cancer Surgery · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04664582 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jewish General Hospital
Last refreshed: 5 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04664582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing